Marathon Money Exclusive: OS Therapies (NYSE: OSTX) CBO Interview Reveals FDA Meeting In Q2 2025 Milestones, $150M Revenue Boost, and $500M Market Opportunity

In this in-depth conversation, we dive straight into the company’s bold plans for the next 12 to 18 months:

Spoiler Alert: Minute 29 is a must-watch. This is where we dig into the specifics of FDA pathways, commercialization timelines, and why OS Therapies believes it can be a transformational player in biotech.

While the video of our exclusive interview with OS Therapies’ Chief Business Officer, Gerald Commissiong, is completely free, you’ll need to sign up for our Future 1%er membership to access it. The Future 1%er membership is entirely free, making this the easiest step toward gaining actionable insights on OSTX and beyond.

Marathon Money: Unlock My OSTX Trading Strategy

OS Therapies Inc. (NYSE: OSTX) We’ve created two powerful trading strategies—a buying strategy and a shorting strategy—tailored to maximize your potential returns based on key milestones like FDA approval, commercialization, and market expansion.

But here’s the deal: these strategies are NOT free.

To access them, you’ll need to sign up for the one-time free CEO interview membership on Marathon Money. This membership gives you exclusive access to my insights, strategies, and the tools I’ll personally use to trade OSTX.

If you are already monthly Member Just Log in

Below are two detailed trading strategies for OS Therapies (NYSE: OSTX)—one for buying and one for shorting. These strategies take into account typical biotech trading patterns, catalysts like FDA milestones, and the inherent risks and volatility of small-cap stocks.